Skip to main content

Table 3 Qualitative image analysis in the exploration and validation cohorts

From: Optimizing acquisition times for total-body positron emission tomography/computed tomography with half-dose 18F-fluorodeoxyglucose in oncology patients

Group

Excellent (score 5)

Good (score 4)

Average (score 3)

Acceptable (score 2)

Non-diagnostic (score 1)

Average score

Exploration cohort

G1 (n = 46)

0

0

0

44 (95.7%)

2 (4.3%)

2.0 ± 0.2*

G2 (n = 46)

0

0

40 (87.0%)

6 (13.0%)

0

2.9 ± 0.3*

G3 (n = 46)

0

0

46 (100%)

0

0

3.0 ± 0.0*

G5 (n = 46)

0

43 (93.5%)

3 (6.5%)

0

0

3.9 ± 0.2*

G8 (n = 46)

10 (11.7%)

36 (78.3%)

0

0

0

4.2 ± 0.4*

Clinical validation cohort

G2 (n = 147)

0

0

143 (97.3%)

4 (2.7%)

0

3.0 ± 0.2*

G3 (n = 147)

0

1 (0.7%)

146 (99.3%)

0

0

3.0 ± 0.1*

G5 (n = 147)

0

85 (57.8%)

62 (42.2%)

0

0

3.6 ± 0.5*

G8 (n = 147)

8 (5.4%)

134 (91.2%)

5 (3.4%)

0

0

4.0 ± 0.3*

Gs (n = 147)

63 (42.9%)

84 (57.1%)

0

0

0

4.4 ± 0.5*

  1. Unless otherwise indicated, data are numbers of patients, and data in parentheses are percentages
  2. *Data are mean ± standard deviation (mean ± SD)
  3. Groups from the clinical validation cohort